TY - JOUR
T1 - T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase
AU - Mellor, Andrew L.
AU - Kahler, David J.
PY - 2009/6/25
Y1 - 2009/6/25
N2 - Mature dendritic cells (DCs) are potent stimulators of T cells that recognize antigens presented by the DCs. In this chapter we describe mature DCs that suppress T cell responses to antigens they present due to expression of the intracel-lular enzyme indoleamine 2,3 dioxygenase (IDO). IDO-competent DCs are a subset of plasmacytoid DCs that can be induced to express IDO under certain inflammatory conditions in humans and mice. Though rare, IDO-expressing DCs acquire potent T cell suppressor activity that may predominate over the T cell stimulatory functions of all other antigen-presenting cells in physiologic environments due in part, to cooperation with regulatory T cells. Thus, IDO-expressing DCs are critical regulators of adaptive immunity that contribute to a wide range of inflammatory disease processes. As such, manipulating IDO expression in DCs using IDO inhibitors or IDO inducers offers considerable opportunities to improve immunotherapies in a range of clinically-significant disease syndromes.
AB - Mature dendritic cells (DCs) are potent stimulators of T cells that recognize antigens presented by the DCs. In this chapter we describe mature DCs that suppress T cell responses to antigens they present due to expression of the intracel-lular enzyme indoleamine 2,3 dioxygenase (IDO). IDO-competent DCs are a subset of plasmacytoid DCs that can be induced to express IDO under certain inflammatory conditions in humans and mice. Though rare, IDO-expressing DCs acquire potent T cell suppressor activity that may predominate over the T cell stimulatory functions of all other antigen-presenting cells in physiologic environments due in part, to cooperation with regulatory T cells. Thus, IDO-expressing DCs are critical regulators of adaptive immunity that contribute to a wide range of inflammatory disease processes. As such, manipulating IDO expression in DCs using IDO inhibitors or IDO inducers offers considerable opportunities to improve immunotherapies in a range of clinically-significant disease syndromes.
UR - http://www.scopus.com/inward/record.url?scp=60549086844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60549086844&partnerID=8YFLogxK
U2 - 10.1007/978-3-540-71029-5-8
DO - 10.1007/978-3-540-71029-5-8
M3 - Article
C2 - 19031026
AN - SCOPUS:60549086844
SN - 0171-2004
VL - 188
SP - 165
EP - 196
JO - Handbook of Experimental Pharmacology
JF - Handbook of Experimental Pharmacology
ER -